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Abstract
A workshop on “The Interface of Pancreatic Cancer with Diabetes, Obesity, and Inflammation: 
Research Gaps and Opportunities” was held by the National Institute of Diabetes and Digestive 
and Kidney Diseases on October 12, 2017. The purpose of the workshop was to explore the 
relationship and possible mechanisms of the increased risk of pancreatic ductal adenocarcinoma 
(PDAC) related to diabetes, the role of altered intracellular energy metabolism in PDAC, the 
mechanisms and biomarkers of diabetes caused by PDAC, the mechanisms of the increased risk of 
PDAC associated with obesity, and the role of inflammatory events and mediators as contributing 
causes of the development of PDAC. Workshop faculty reviewed the state of the current 
knowledge in these areas and made recommendations for future research efforts. Further 
knowledge is needed to elucidate the basic mechanisms contributing to the role of 
hyperinsulinemia, hyperglycemia, adipokines, and acute and chronic inflammatory events on the 
development of PDAC.
Keywords
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Pancreatic ductal adenocarcinoma (PDAC) is projected to be the second leading cause of 
adult cancer mortality by 2030.1 Pancreatic ductal adenocarcinoma has a complex 
association with diabetes mellitus (DM). The increased incidence of pancreatic cancer in 
diabetic populations has been observed repeatedly in epidemiologic studies with a relative 
risk that ranges from 1.5 to 2.0.2 Importantly, among a subset of patients with new-onset 
DM, the diagnosis of DM occurred 24 to 36 months prior to the diagnosis of PDAC in close 
to 1% of such patients.3 These facts illustrate that DM and PDAC demonstrate “dual 
causality” in that DM is a risk factor for the development of PDAC, and conversely, PDAC is 
a presumed cause of DM in a subset of cases. The mechanisms of these causal relationships 
are unclear, as are the diagnostic criteria for differentiating type 2 DM (T2DM) from DM 
that occurs in the setting of PDAC or other forms of diabetes related to pancreatic exocrine 
disease, sometimes referred to as T3cDM or pancreatogenic DM. In this article, we use the 
following nomenclature: (1) pancreatic cancer–related diabetes that has its onset in the 
months just prior to or after the diagnosis of PDAC; (2) T2DM to refer to hyperglycemia 
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usually associated with obesity, insulin resistance, and treated with oral medications and 
sometimes insulin; (3) postpancreatitis-related diabetes to refer to diabetes occurring in the 
setting of acute or chronic pancreatitis. This article does not discuss diabetes associated with 
other types of pancreatic disease or type 1 DM, which is not a risk factor for PDAC.4,5 
These are important considerations clinically given that PDAC has an overall 5-year survival 
rate of 7% to 8%6 and recognition that pancreatic cancer–related diabetes may provide the 
means to diagnose PDAC at a potentially curable point in its natural history. Risk factors 
associated with PDAC include T2DM and obesity, disorders that are associated with chronic 
caloric excess.
The relationship between PDAC and total body energy excess and altered cellular energy 
production within pancreatic cancer cells and its local microenvironment is complex, but 
suggests the importance of energy balance in the development and maintenance of PDAC.
Given the challenges inherent in treating advanced PDAC, understanding the 
pathophysiology governing these key modifiable risk factors for pancreatic cancer is 
important for reducing the incidence of this lethal disease. Toward this end, the National 
Institute of Diabetes and Digestive and Kidney Diseases developed a workshop focused on 
exploring what is currently known about these relationships in order to outline areas where 
significant gaps in knowledge can be considered for future research and targeted funding 
opportunities. The symposium was organized around 4 sessions designed to examine these 
complex relationships: (1) The Role of Altered Energy Metabolism in PDAC, (2) PDAC as a 
Cause of Diabetes, (3) Obesity as a Cause/Risk Factor for PDAC, and (4) Inflammation and 
the Immune System as a Cause/Mediator of PDAC.
THE ROLE OF ALTERED ENERGY METABOLISM IN PDAC
Mechanisms of Increased Risk for PDAC in T2DM
The statistics regarding the prevalence of T2DM in the United States are sobering. The 
Centers for Disease Control and Prevention estimates that 30.3 million individuals were 
living with diabetes in 2017. The underlying causes are complex, but T2DM is clearly linked 
to increased obesity rates due to excess calorie consumption and reduced energy expenditure 
and has been associated with insulin resistance, production of proinflammatory and 
diabetogenic adipokines by adipose tissues and adipose-associated macrophages, excessive 
hepatic glucose release, and beta cell failure to meet the increased insulin secretion 
demands.
To better understand the approximately 2-fold increased risk of PDAC in T2DM, it is 
important to delineate how T2DM may contribute to the development of PDAC. It is 
recognized that T2DM is associated with insulin resistance and islet dysfunction, including 
disordered insulin and glucagon secretion. Insulin resistance is partly due to the production 
of proinflammatory and diabetogenic adipokines by adipose tissues and resident 
macrophages and excessive reactive oxygen species generation.7 In addition, there is a 
propensity by the liver to excessively release glucose. To prevent hyperglycemia under the 
above circumstances, there is increased secretion of insulin by the beta cells. The increase in 
insulin levels raises insulinlike growth factor 1 (IGF-1) levels.7 Both insulin and IGF-1 
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activate phosphoinositide 3-kinase that enhances mitogenic and prosurvival signaling and 
activate the RAC-α serine/threonine-protein kinase (AKT) that in turn activates mammalian 
target of rapamycin (mTOR), leading to enhanced protein synthesis.7
Fat-derived adipokines also activate AMP-activated protein kinase that further enhances 
protein synthesis and modulates cell polarity and division.7 In addition, adipocytes release 
free fatty acids, leptin, plasminogen activator inhibitor 1 and lipocalin 2, which combine to 
enhance proinflammatory signals and promote insulin resistance.8 Lipocalin 2, which is also 
produced by cancer cells and macrophages, induces a proinflammatory tumor 
microenvironment (TME) in PDAC.8 Moreover, adipose tissue macrophages produce tumor 
necrosis factor α, galectin 3, interleukin 6 (IL-6), and IL-1β, exacerbating inflammatory 
signaling, whereas lipolysis releases acetyl-CoA that enhances hepatic insulin resistance and 
promotes mitogenesis and autophagy.9 Galectin 3 is an important component of 
inflammation-driven insulin resistance.10 It is overexpressed in chronic pancreatitis and can 
enhance Kras activity and may therefore contribute to malignant transformation in chronic 
pancreatitis and to PDAC initiation and progression.11 Biochemical studies also point to 
attenuated positive feedback regulation of insulin receptor (IR) substrate 1 by mTOR 
complex 1 (mTORC1) leading to decreased levels of IRs, FOXO1, and GLUT4 in T2DM, 
thereby inducing insulin resistance in adipose tissue.12
The persistent and excessive demand for insulin in the context of a systemic 
proinflammatory state results in prolonged beta cell stress that is exacerbated by activated 
intraislet macrophages, endoplasmic reticulum stress pathway activation, and oxidative 
stress, all modulated by genetic susceptibility factors.13,14 There is also impaired processing 
of proinsulin to insulin, intraislet vascular perturbations, and loss of highly metabolic beta 
cells that normally function as pacemakers to properly propagate insulin oscillatory 
secretory dynamics.15–17 As a consequence of all these alterations, there is progressive 
deterioration in beta cell function with eventual beta cell failure and clinically evident 
T2DM.
An underappreciated aspect of the dispersal of endocrine islets throughout the exocrine 
pancreas is that a portion of the blood draining from the islets is distributed into an 
intrapancreatic portal circulation that likely exposes the adjoining acinar and ductal cells to 
very high levels of insulin that exert trophic effects on these cells.18,19 Moreover, high 
insulin levels readily activate the IR and IGF-1 receptor (IGF-1R), as well as their hybrid 
forms (IR–IGF-1R), which may lead to excessive activation of mitogenic signaling cascades 
in precursor lesions arising in these regions of the pancreas.20 Thus, a prolonged insulin-
resistant state in combination with many years of hyperinsulinemia, a tendency toward 
hyperglycemia and slow but progressive deterioration in beta cell function, may combine 
with a proinflammatory state to increase the risk of developing PDAC.13,21
Chronic hyperglycemia is associated with increased levels of advanced glycation end 
products (AGE) that activate the receptor for AGE (RAGE) that sustains chronic 
inflammation pathways and activates Kras.22,23 Receptor for AGE, a member of the 
immunoglobulin super family, also binds members of the S100 family of proteins that have 
been implicated in inflammation and cancer, including PDAC.24 Thus, excessive RAGE 
Abbruzzese et al. Page 4













activation may contribute to the higher incidence of PDAC in T2DM and may lead to 
accelerated PDAC growth in new-onset diabetes because such patients often exhibit 
deterioration in glycemic control.
There is also strong evidence that obesity is associated with an increased risk of pancreatic 
cancer.25 In fact, the anticipated increase in pancreatic cancer incidence and deaths may be 
at least partially attributed to the obesity endemic. There are many possible mechanisms by 
which obesity leads to (pancreatic) cancer, including insulin resistance with resulting 
hyperinsulinemia and inflammation.26 Nonsteroidal anti-inflammatory drugs can attenuate 
pancreatic cancer development in a genetically engineered mouse model possibly suggesting 
an important role for tissue inflammation in this disease.27,28 Obesity-associated tissue 
inflammation is thought to create a fertile microenvironment conducive to tumor initiation 
and/or promotion. Recent evidence indicates that in addition to measures of general obesity, 
for example, body mass index (BMI), visceral adiposity carries a strong association to 
metabolic diseases and gastrointestinal cancers, including pancreatic cancer.29
Modulating Risk: The Effects of Metformin and Other Therapies for Diabetes on Pancreatic 
Cancer Risk
Given the risk of PDAC in patients with T2DM, it is important to identify interventions that 
can mitigate this risk. Li and colleagues30 demonstrated in a hospital-based case-control 
study that individuals with diabetes treated with metformin had a 60% reduction in 
incidence of pancreatic cancer compared with never users. Thus, while the effect of 
metformin on survival of individuals with diabetes with established pancreatic cancer 
appears to be negligible, a decreased risk of developing pancreatic cancer in diabetic patients 
was found in a subsequent meta-analysis.31 The mechanisms of metformin’s effects on 
pancreatic cancer risk are not fully understood but appear to be diverse, including direct 
effects on cancer cells inhibiting mitochondrial respiratory complex I and activation of 
AMP-activated protein kinase/mTOR pathway that reduces cell proliferation and induces 
apoptosis. Indirect effects also include its ability to lower insulin levels by increasing hepatic 
sensitivity to insulin and as yet poorly understood effects on the TME of PDAC.32 Attempts 
to uncover other relationships between the use of medications to control blood sugar in 
patients with T2DM and an enhanced risk of PDAC have yielded only provocative 
correlations. For example, the use of sulfonylureas and thiazolidinediones in patients 
withT2DM has shown slight and statistically insignificant increases in PDAC risk of 1.2- 
and 1.6- fold, respectively, whereas the tenuous association between incretin use and 
increased PDAC incidence is likely due to the presence of undiagnosed PDAC that has 
become evident shortly after initiation of incretin therapy.33,34 Similarly, the association 
with insulin use in new-onset diabetes is likely due to the deterioration of glycemic control 
caused by the underlying PDAC.33,35
The Role of Altered Intracellular Metabolism in PDAC
In addition to the deregulated systemic physiology conferred by disruption of energy 
homeostasis discussed previously, metabolic processes within the cells that constitute a 
pancreatic tumor are also rewired.36 In the malignant cells of a pancreatic tumor, these 
alterations are mediated both by oncogene-driven programs and the unique physiology of the 
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tumor. Pancreatic tumors are typified by a dense, fibrotic stroma that inhibits vascular 
function and thus nutrient and oxygen delivery.37 To survive and proliferate under these 
circumstances, mutant Kras expression rewires metabolic networks that facilitate redox 
balance, bioenergetics, and anabolic metabolism.38–40 These pathways are fueled by 
nutrients recycled through autophagy41,42 and those scavenged by nonspecific bulk 
extracellular space engulfment (via the process macropinocytosis)43 and overexpressed 
nutrient importers.38,44 Collectively, the rewiring of metabolism in pancreatic cancer cells, 
enforced by the constraints of the TME and conferred by oncogene-driven pathways, 
engages nutrient scavenging mechanisms and drives efficient nutrient utilization to fulfill the 
shortcomings of insufficient vascularization. The recent detailing of these processes has 
revealed metabolic vulnerabilities in preclinical models, several of which are now being 
explored in clinical trials.36
Beyond the cell autonomous alterations within the malignant cells, more recent studies have 
revealed how metabolic crosstalk networks among cells in a pancreatic tumor are also 
deregulated. Malignant cells can constitute as little as 10% of the total cellular content of a 
pancreatic tumor.37 Accordingly, the nonmalignant cells play an important role in shaping 
the metabolic nature of the TME and facilitating tumor growth.45 These interactions can be 
classified generally into 2 categories. First are the cooperative interactions between 
malignant and nonmalignant cells that support metabolism in the cancer cells. The second 
type of interaction is competitive and occurs between tumor cells and the antitumor immune 
response.
A notable cooperative interaction is the nutrient exchange pathway between pancreatic 
cancer cells and activated pancreatic stellate cells (PSCs).46 In this example, pancreatic 
cancer cells induce autophagy in the PSCs. This leads to protein breakdown through 
autophagy and the release of nonessential amino acids. Among these, the pancreatic cancer 
cells avidly capture alanine and utilize this to support mitochondrial metabolism and the 
biosynthesis of cellular building blocks. Importantly, alanine can be utilized in metabolism 
in place of glucose and glutamine, 2 biosynthetic substrates that are rate limiting in the 
pancreatic TME. Moreover, blocking this metabolic crosstalk pathway by inhibiting 
autophagy specifically in the PSCs leads to a dramatic decrease in tumor growth.
Pancreatic tumors are profoundly immune suppressive and have proven highly resistant to 
immunotherapies.47 Indeed, there is a growing appreciation that local nutrient depletion and 
waste accumulation play active roles in facilitating tumor immune suppression.45 Cytotoxic 
T-cells, which are intrinsically less fit than oncogene-driven cells at obtaining nutrients, are 
forced to compete for the limited carbohydrates and amino acids in a tumor to mount an 
effective antitumor immune response. For example, the limited antitumor T-cell response 
observed in melanoma and sarcoma models has been directly linked to glucose deprivation,
48,49 and high levels of lactate drive the polarization of anti-inflammatory macrophages.50 
Given that mutant Kras-expressing pancreatic cancer cells avidly consume glucose and 
release lactate (so-called, Warburg metabolism),38 these mechanisms are likely to play an 
immune-suppressive function in pancreatic cancer. Furthermore, alternatively polarized, 
anti-inflammatory macrophages and cancer cells can deplete tumors of the amino acids 
arginine and tryptophan.51 This limits the antitumor T-cell response and favors the 
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differentiation of T-cells into anti-inflammatory T-regulatory cells. The importance of many 
of these competitive metabolic interactions remains to be determined in pancreatic cancer. 
However, these represent exciting new potential opportunities to leverage immunotherapy in 
pancreatic cancer patients.
Integrating Information From Rodent Models to Human Disease
The human pancreas is particularly challenging to study. Accordingly, the sequence of 
molecular events leading to PDAC is derived from study of animal models and examination 
of advanced human PDAC samples. Serial biopsies or sampling of pancreatic tissue in living 
humans is rarely done because of safety concerns. A further challenge is that the pancreas 
rapidly undergoes auto-digestion after death, so detailed molecular analyses of the human 
pancreatic exocrine and ductal tissue (eg, RNA analysis) are quite limited. In contrast, 
human islets for research have become more readily available for research over the past 
decade as the result of human islet isolation programs related to allograft islet 
transplantation.52 This availability has allowed for a range of in vitro studies and in vivo 
studies following the transplantation into immunodeficient mice, similar to the patient-
derived xenograft approach often used to study human tumors. This has led to a large 
number of investigators pursuing the molecular characterization and functional analysis of 
human islets. During islet isolation, enzymatic digestion to “free” islets (representing 1%–
2% of pancreatic mass) results in damage or destruction of pancreatic acinar and ductal 
tissue. Thus, the recent availability of human islets that has led to an increase in knowledge 
about human islet biology has not been accompanied by greater availability of human 
pancreatic exocrine or ductal tissue for research. This challenge has led to development of a 
variety of rodent models of PDAC that utilize genetic or chemical manipulations.53,54
Important for this discussion is the realization that human islet biology and rodent islet 
biology have both similarities and differences. For example, pancreatic islet and exocrine 
cells share common embryologic lineage, but the sequence of events and molecular markers 
in humans and rodents have several notable differences. It has also become clear that there 
are considerable differences in islet cell composition and cell arrangement, proliferative 
capacity, function, and gene expression in human islet cells compared with the response to 
insulin resistance.55–57 Furthermore, rodent models of several forms of monogenic diabetes 
may not recapitulate the features of the human disease. Rodent models of type 1 DM and 
T2DM, although having some features of the human disease, do not completely mirror 
human physiology or pathophysiology involving insulin secretion, insulin resistance, and 
adipocyte biology. Likewise, the fidelity of rodent models of PDAC or its early lesions is 
uncertain, and new model systems involving primary human pancreatic epithelial cells, 
inducible pleuripotent stem cells, or tumor cell organoids are under developments as new 
types of preclinical models.58
Research Gaps and Opportunities
• Conduct further studies on pathogenesis and mediators of PDAC, especially 
insulin resistance, obesity, and inflammation.
• Improve understanding of how current model systems can be used to understand 
the early events in human PDAC.
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• Develop new animal and cellular models of human PDAC, its early lesions, and 
tumor-associated microenvironment.
• Develop new approaches to define and characterize normal human pancreatic 
exocrine and ductal biology.
• Develop methods to study cellular metabolism in vivo.
• Characterize the cellular compartments that make up the pancreatic TME.
• Refine understanding of the mechanisms contributing to the immunosuppressive 
microenvironment of PDAC.
PANCREATIC CANCER AS A CAUSE OF DIABETES
Pathophysiology of Pancreatic Cancer–Related Diabetes
There is growing evidence that PDAC frequently causes DM.59 Nearly 85% of PDAC 
patients have DM or hyperglycemia, often manifesting in the 2 to 3 years preceding their 
cancer diagnosis.59 In addition, patients with new-onset diabetes have a 5- to 8-fold 
increased risk of being diagnosed with PDAC within 1 to 3 years of developing diabetes.59 
Paradoxically, this form of DM occurs in the face of ongoing, often profound, weight loss 
and frequently resolves with cancer resection.59,60
Of the many hypotheses for why PDAC causes DM is a paraneoplastic phenomenon caused 
by 1 or more tumor-secreted products that cause both insulin resistance and an inadequate 
beta cell response to stimuli, leading to beta cell failure.59,60 Apart from the clinical and 
epidemiological evidence, this notion is supported by laboratory data that the supernatant 
from cultured PDAC cell lines inhibits insulin secretion. Similarly, PDAC exosomes inhibit 
insulin secretion. In a set of studies, these effects were attributed to adrenomedullin,61,62 and 
it has been suggested that PDAC-DM is an exosomopathy,62,63 a disease caused by 
exosomes, a novel hypothesis that needs further study. Another candidate mediator is 
neuromedin U, a peptide overexpressed in pancreatic cancer and chronic pancreatitis 
(pancreatogenic diabetic states) that may be an important mediator of insulin resistance and 
diabetes in the setting of PDAC.58 Such a finding, if confirmed, could potentially be used as 
a biomarker for early detection of patients with PDAC in patients presenting with new-onset 
diabetes. One of the impediments to progress in this area has been the difficulty in 
developing animal model(s) of PDAC-DM. Because hyperglycemia is one of the earliest, 
albeit nonspecific, harbingers of PDAC, understanding the molecular mechanisms of PDAC-
induced DM is likely to lead to discovery of a biomarker that may lead to early detection of 
PDAC.64 Differentiating T2DM from pancreatic cancer–related diabetes would allow for 
early detection of PDAC in subjects with new-onset hyperglycemia and DM. In addition to 
the effects of inflammatory or other products released by the tumor itself, insulin secretory 
deficits may be due to the inhibitory effects of activated PSCs, an impairment of incretin 
secretion, or the inhibitory effects of cytokines released by macrophages recruited by the 
tumor to the pancreas.
Beta cell loss of function and apoptosis have been shown in a model of PSC/beta cell 
coculture,65 and the cytokine interferon γ has been shown to reversibly inhibit the nuclear 
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translocation of the transcription factor pancreatic duodenal homeobox 1 in models of 
pancreatitis-induced pancreatogenic diabetes.66
The suppression of hepatic glucose production is an important component of insulin’s 
regulation of glucose homeostasis, and the availability of hepatic IRs has been shown to be 
regulated by the islet peptide pancreatic polypeptide (PP).67 A deficiency in PP has been 
shown to be a reversible cause of hepatic insulin resistance,68 and a deficiency in PP has 
now been shown to be associated with PDAC.69,70 Insulin sensitivity may be impaired by 
inflammatory cytokines such as inhibitor of nuclear factor κB kinase subunit β,71 or the loss 
of peptide mediators of hepatic IR availability such as PP.72 Incretins such as glucose-
dependent insulinotropic polypeptide (GIP) stimulate the release of insulin as well as PP.73 
Reduced GIP levels have been observed in PDAC, possibly due to an increase in dipeptidyl 
peptidase IV levels induced by the tumor,74 and this process is reversible by resection of the 
tumor.70 Therefore, deficient PP and GIP levels may be both a cause of PDAC-DM and a 
biomarker of the condition.
Early Detection of PDAC-Induced Diabetes
The screening of all patients with new-onset diabetes is not currently feasible because 
approximately only 1% of these individuals older than 50 years will develop PDAC within 2 
to 3 years. Therefore, various approaches have been undertaken to identify PDAC-DM 
specifically or to differentiate the 8% to 10% of patients with new-onset diabetes who harbor 
pancreatogenic, or T3cDM, and the more common T2DM. Using isobaric tags for relative 
and absolute quantification (iTRAQ) coupled with liquid chromatography–tandem mass 
spectrometry and immunoassays (Luminex, Rules Based Medicine, enzyme-linked 
immunosorbent assays, and Western blotting), the Pancreas Research Group at the 
University of Liverpool, United Kingdom, has conducted studies on cohorts of subjects with 
PDAC. Using these methods, in collaboration with the University College London, the group 
has found that CA 19–9 is increased up to 24 months prior to the diagnosis of PDAC75 and 
that thrombospondin 1 is decreased in PDAC.76 By combining these analytes with other 
markers, the Liverpool group has identified a panel of proteins that are highly discriminatory 
for T3cDM. Validation studies are currently being carried out in collaboration with the 
PANDIA study, the United Kingdom’s first biobank of samples from subjects with newonset 
diabetes for PDAC detection.
The concept of assessing a panel of circulating immunoregulatory markers, rather than only 
a single protein, has been explored extensively in cancer diagnostics, by the group at Lund 
University in Sweden.77 This has been applied to the study of markers of PDAC, where a 
panel of approximately 25 serum biomarkers has been identified.78,79 These markers 
displayed a characteristic set of profiles on PDAC patients compared with control subjects, 
those with chronic pancreatitis and autoimmune pancreatitis, or with other inflammatory 
conditions or malignancies.80 Work by Borrebaeck et al suggests that by targeting some of 
the key immunoregulatory molecules that are abnormally expressed in PDAC the 
multiplexed approach overcomes the limitations of a single protein marker and has shown 
high sensitivity and specificity in subsequent validation studies.81 Further investigations are 
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underway to determine the feasibility of this detection method in those with new-onset 
diabetes and other patients at high risk of PDAC.
Research Gaps and Opportunities
• Conduct further studies on pathogenesis and mediators of pancreatic cancer–
related diabetes.
• Develop animal models of pancreatic cancer–related diabetes.
• Validate cytokine markers associated with impaired beta cell function and 
apoptosis in PDAC.
• Understand the role of microvesicles and exosomes in pancreatic cancer and 
T3cDM.
• Conduct preclinical trials of anti-inflammatory agents on pancreatic cancer–
related diabetes.
• Validate circulating biomarkers of pancreatic cancer–related diabetes.
• Confirm diagnostic criteria to differentiate pancreatic cancer– related diabetes 
and T3cDM from T2DM.
• Develop clinical algorithms that can predict pancreatic cancer– related diabetes 
among subjects with new-onset diabetes.
OBESITY AS A CAUSE/RISK FACTOR FOR PDAC
The Risk of Obesity and the Role of Bariatric Surgery
Although the overall rate of new cancer diagnoses has decreased since the 1990s, a dramatic 
increase has been observed for obesity-associated cancers.82 Premorbid obesity adversely 
influences PDAC-related mortality in a dose-dependent manner.83,84 In addition, a high BMI 
has been associated with an increased risk of PDAC, age at onset, and overall survival.83,84
The pathogenesis of obesity-related diseases begins with positive energy balance and 
triglyceride deposition in the adipose tissue. When excess triglyceride cannot be fully 
deposited in the adipose tissue, ectopic fat deposition occurs in organs such as the liver and 
pancreas. In the liver, triglyceride deposition leads to oxidative stress and inflammation, 
which leads to steatohepatitis, cirrhosis, and hepatocellular carcinoma. Increasing evidence 
indicates that a similar pathway may occur in the pancreas. Both free fatty acids and 
inflammatory mediators occur in high amounts in the pancreas of obese mice,85 and tumor 
growth is accelerated in obese animals.86 Hepatic and pancreatic fats are also increased in 
obese individuals.
Following weight loss after bariatric surgery, there is rapid resolution of both hepatic and 
pancreatic fats.87 Insulin resistance and circulating levels of some inflammatory mediators 
rapidly normalize following weight loss.88 Weight loss induced by bariatric surgery in 
humans reduces all-cause cancer mortality by 40% to 60%.89,90 A recent matched 
retrospective study showed that the risk of PDAC was significantly lower among those 
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patients who had undergone bariatric surgery compared with control patients.91 However, 
bariatric surgery in these trials has been limited to individuals with severe obesity (mean 
BMI >40 kg/m2) in whom substantial weight loss (mean >30% total body weight) has been 
achieved. Whether a similar reduction in the incidence and/or mortality of pancreatic and 
other cancers could be achieved in patients with less severe obesity or with lesser amounts of 
weight loss is not known. This study suggests that intentional weight loss may reduce the 
risk of cancer specifically in obese patients. Further studies into the role of intentional 
weight loss via bariatric surgery and/or other interventions such as lifestyle interventions, 
pharmacotherapy, or less invasive surgical/endoscopic procedures are needed to understand 
their role and possible mechanisms in cancer prevention.
Mechanisms of Obesity Risk and Inflammation
While there have been many epidemiological studies indicating the dangers of obesity in 
promoting and increasing the risk of PDAC development, many fundamental questions 
regarding the molecular mechanisms underlying the detrimental effects of obesity remain 
unanswered. Plausible mediators include insulin, estrogens, and inflammatory molecules 
such as adipokines.84
Using genetically engineered mouse models of PDAC and diet-induced obesity mouse 
models that mimic the obesity phenotype, it has been shown that diet-induced obesity acts as 
an inflammatory stimulus to trigger increased KRasG12D signaling and that cyclooxygenase 
2 is critical in the inflammatory loop that leads to inflammation, increased fibrosis, 
KRasG12D signaling, pancreatic intraepithelial neoplasia lesion progression, and accelerated 
tumor growth.28 Moreover, the novel adipokine, lipocalin 2, which is secreted by adipose 
tissue in obese subjects, has been linked to promoting the development of obesity-associated 
PDAC and stimulating a receptor-mediated proinflammatory response in the TME.8
Another factor that suggests a possible link between, obesity, diabetes, and PDAC may 
involve the RAGE. This factor is present in PDAC and capable of influencing the critical 
mechanisms involved in the Ras-induced inflammation feed-forward loop that is observed as 
a result of obesity-associated PDAC.28 A recent review summarizes signals from the adipose 
tissue microenvironment that are associated with obesity and cancer in humans,92 but there 
are currently no studies in PDAC, highlighting an important knowledge gap. Further insights 
into these relationships will allow the development of novel preventative approaches for 
obese patients at increased risk of developing PDAC.
Role of Visceral and Peripancreatic Fat on Carcinogenesis
Although the BMI is widely used as a marker for general adiposity, several studies have 
identified that visceral obesity has a stronger correlation to the metabolic syndrome, insulin 
resistance, and certain gastrointestinal malignancies, including PDAC.93 The close 
proximity to visceral organs and drainage via the portal system may explain the strong 
correlation of inflamed visceral adipose tissue (VAT) in obese subjects with metabolic 
dysfunction and gastrointestinal cancer.
The importance of VAT on PDAC development was suggested by studies using genetically 
engineered mouse models. Conditional KRasG12D (KC) mice fed a diet high in fats and 
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calories gained significantly more weight compared with lean mice fed a control diet; 
developed metabolic dysfunction, including hyperinsulinemia and hyperleptinemia; and 
were characterized by VAT expansion and inflammation.94–96 Obese KC mice developed a 
stronger fibroinflammatory reaction in the pancreas and more PDAC than their lean 
littermates.94 Interestingly, the increased incidence of PDAC in obese KC mice was largely 
seen in male mice, suggesting a role for sex hormones in this process.94 This correlated with 
an expansion of VAT in obese male KC mice, whereas female obese KC mice gained 
adipose tissue preferentially subcutaneously.96 Overall, there is strong evidence emphasizing 
an important role of VAT and VAT inflammation in PDAC. Further studies are clearly 
needed to explore the underlying mechanisms, to investigate sex- and adipose depot-specific 
differences, and to develop strategies aimed at reducing VAT inflammation.97
PDAC and the Microbiome
Recent data suggest that the human microbiome could shed light on how to better tackle 
prevention, early detection, and treatment of PDAC.98–100 Many diseases are now associated 
with changes in the microbiome composition, and there is increasing evidence of bacterial 
microbiota playing a key role in carcinogenesis. Preclinical and clinical evidence suggests 
that bacteria are likely to influence the interface of PDAC with diabetes, obesity, and 
inflammation.101 Pancreatic ductal adenocarcinoma has been recognized as an 
inflammation-driven cancer. Bacteria can induce chronic inflammation via molecular pattern 
recognition receptors. Pattern recognition receptors and associated signaling molecules have 
been implicated in the pathogenesis of inflammation-driven cancers. The gut microbiome 
may influence the efficiency of intestinal calorie absorption and contribute to obesity. The 
mechanisms may involve an association of obesity with diabetes, chronic low-level 
inflammation, increased hormones, and adipokines. Diabetes, obesity, and chronic 
pancreatitis can lead to chronic inflammation, which may promote pancreatic 
carcinogenesis.102 Changes in the oral microbiome have also been associated with an 
increased risk of PDAC, and presence of distinct oral microbial community profile for 
PDAC may be useful as a biomarker of the disease. Differential abundance in oral bacteria 
and the microbiome of the pancreatic secretions or stool may be associated with risk of 
PDAC. Research on the microbiome and PDAC could lead to innovative strategies for 
prevention, early detection, and targets for intervention.
Research Gaps and Opportunities
• Investigate the impact of bariatric surgery and weight loss on PDAC and explore 
the underlying mechanisms, including GIPs, inflammation, and gut microbiome.
• Conduct mechanistic studies in preclinical models to understand the link 
between VAT and pancreatic fibroinflammatory diseases, including pancreatitis 
and PDAC.
• Develop strategies which target the obesogenic signaling network and feedback 
loops in VAT and pancreas, including the effect of US Food and Drug 
Administration–approved drugs (eg, metformin, statins).
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• Study how factors secreted from adipose tissue and the adipose cellular 
microenvironment affect the pancreatic tissue microenvironment of pancreatic 
diseases.
• Develop and characterize the best preclinical models that mimic human obesity-
associated PDAC.
• Validate preclinical findings of obesity-associated PDAC using human-derived 
samples, particularly adipose tissue.
• Assess the impact of intentional weight loss programs, for example, exercise 
interventions, to understand their role and possible mechanisms in cancer 
prevention.
• Develop markers of obesity-associated development of PDAC to facilitate 
identification of individuals with obesity who are at particular risk of PDAC and 
other cancers in efforts to recommend weight loss interventions.
• Explore the obesity-associated changes in the gut microbiome and their impact 
on fibroinflammatory diseases of the pancreas.
• Identify the metabolites and their molecular pathways linking changes in gut 
microflora to pancreatic diseases.
INFLAMMATION AND THE IMMUNE SYSTEM AS A CAUSE/MEDIATOR OF 
PDAC
Chronic inflammation of the pancreas or chronic pancreatitis is a major risk factor for 
developing PDAC. Activated PSCs play a central role in chronic pancreatitis progression by 
regulating the synthesis and degradation of extracellular matrix proteins. Activation of PSCs 
is increased by cytokines from injured acinar cells and immune cells. The mechanisms by 
which macrophages trigger and sustain the fibrotic processes by interacting with PSCs were 
recently elucidated by Habtezion and colleagues, and interfering with these immune signals 
resulted in inhibition of the inflammation and fibrosis in experimental models of chronic 
pancreatitis.103 Environmental factors such as alcohol and smoking are also well-known risk 
factors for chronic pancreatitis and pancreatic adenocarcinoma. The role of inflammation 
and cross talk between immune cells and PSCs mediated via IL-22 signaling were described 
in smoking-induced progression of experimental chronic pancreatitis.104 Similarly, smoking-
related effects in promoting experimental pancreatic cancer involving pathways such as IL-6 
and histone deacetylases in immune and cancer cell interactions were delineated recently.105 
Thus, immune-related signals are important in promoting pancreatitis and pancreatic cancer 
progression, and understanding complex multicellular interactions that lead to the 
development and progression of PDAC will be of great significance.
Pancreatic ductal adenocarcinoma remains with a poor prognosis despite advances in 
elucidation of underlying molecular mechanisms, genomic/epigenetic/transcriptome 
analyses, early detection strategies, risk stratification, and targeted therapies. Moreover, most 
cases of PDAC are resistant to treatment with immunotherapies such as immune checkpoint 
antibodies. Accumulating evidence indicates that inflammatory processes play a pivotal role 
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in promoting the malignant transformation, growth, and metastasis of pancreatic cancer. 
Kras mutations induce aberrant cytokine and chemokine expression in tumor epithelial cells 
and subsequently remodel the TME by recruiting immune cells such as macrophages, 
dendritic cells (DCs), and myeloid-derived suppressive cells, which promote tumor growth. 
As a result, reprograming these and other cells in the PDAC TME in an effort to create an 
immunostimulatory environment is an attractive approach that may hold the key to enabling 
efficacious immunotherapy.
Because PDAC is often followed by distant metastatic relapse after complete surgical 
resection and, as mentioned previously, generally fails to respond to immunotherapy, a better 
understanding of the factors affecting metastasis is also critical for the development of more 
effective treatments. Utilizing an orthotopic mouse model of PDAC that resembles the 
human disease in its genetics, histopathology, and clinical manifestations and also 
predictably metastasizes to the liver has permitted a systematic investigation of the 
metastasis-associated immune response.106 Recent studies of these mice by Engleman and 
colleagues revealed that early metastases are associated with dense networks of CD11b
+CD11c+MHC-II+CD24+CD64lowF4/ 80low cells, which develop from monocytes and 
promote metastasis by inducing the expansion of regulatory T-cells and inhibiting the 
development of cytotoxic T-cells.107 Phenotypically similar DCs accumulate at primary and 
secondary sites in other PDAC models and in human PDAC.107 Given the importance of 
these DCs in tumor metastasis, groups have been working on immunotherapeutic strategies 
designed to reprogram them into immunostimulatory antigen-presenting cells. One such 
strategy is based on the discovery that tumor-binding immunoglobulin G antibodies in 
combination with certain DC-stimulating molecules enable tumor-associated DCs to take up, 
process, and present a wide range of tumor antigens to T-cells, which then proliferate and 
attack tumors throughout the host. This approach can overcome tumor-mediated 
immunosuppression and lead to eradication of metastases, as well as primary tumors in a 
wide range of cancers in mice, including PDAC.108
Despite this promising research, metastatic PDAC remains a challenging disease, as tumor 
cells tend to disseminate into the circulation and colonize distant organs and compartments.
109 Metastatic PDAC has been postulated to involve several different mechanisms, including 
the selection of mutant clones in the primary tumor that are fated to metastasize, epigenetic 
modifications in the primary tumor, circulating cells that travel in clusters, and the 
establishment of a premetastatic niche in distant organs involving proinflammatory and 
immune cells and the interplay with exosomes.110 Work by Rustgi et al (manuscript 
submitted) now supports the notion that epithelial plasticity in the spectrum of epithelial-
mesenchymal transition and mesenchymal-epithelial transition influences not only the 
metastatic potential of PDAC but also the specification of which organ will be the recipient 
of metastatic PDAC cells for colonization, referred to as metastatic organotropism. This 
opens up new approaches to therapy that may involve different agents for primary PDAC 
versus PDAC in the liver versus lung.
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Research Gaps and Opportunities
• Understand how the immune/inflammatory environment promotes PDAC or its 
progression.
• Define the role of activated PSCs, immune cells, and antigen-presenting cells in 
PDAC progression and whether targeted interventions of these cells may be 
beneficial.
• Identify markers and regulators of the metastatic potential of PDAC.
• Define local and metastatic immune cell networks and determine how to 
reprogram them in order to generate system-wide antitumor immunity.
• Define metastatic organotropism pathways with goals of developing specific 
targets to target the different metastatic PDAC sites.
• Validate experimental findings using human samples from patients undergoing 
therapeutic trials.
SUMMARY
Pancreatic cancer is a challenging malignancy with an increasing incidence and high 
lethality. The disease has complex relationships with diabetes and obesity that are only 
partially understood. Diabetes can be both a risk factor and early manifestation of pancreatic 
cancer. Obesity is strongly linked to increased risk of pancreatic cancer, but the specific 
mechanisms that contribute to pancreatic carcinogenesis are not clear. This symposium 
reviewed the current understanding of the role that altered energy metabolism plays in 
pancreatic cancer risk, data supporting the epidemiologic evidence that pancreatic cancer 
can be a cause of diabetes, observations linking obesity to pancreatic cancer, and 
inflammation and immune system dysfunction as critical processes contributing to 
pancreatic cancer development, metastases, and therapeutic resistance. Specific research 
gaps and scientific opportunities have been outlined as a guide to funding agencies and 
investigators working in this field.
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